OSE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.56 EUR | -0.71% |
|
+3.35% | +29.91% |
| Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
| Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 50.21 | 55.22 | 129 | 187.7 | 123.4 | 119.9 | 119.9 | - |
| Enterprise Value (EV) 1 | 45.1 | 40.86 | 119.2 | 186.5 | 138.1 | 80.55 | 166.5 | 118.7 |
| P/E ratio | 9.71 x | -11.9 x | -6.79 x | -11.1 x | -6.95 x | -3.63 x | -12.9 x | 2.78 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.05 x | 2.13 x | 12.4 x | 7.14 x | 6.74 x | 36.2 x | 3.17 x | 1.62 x |
| EV / Revenue | 1.84 x | 1.57 x | 11.4 x | 7.09 x | 7.55 x | 36.2 x | 4.4 x | 1.61 x |
| EV / EBITDA | 9.09 x | -35.6 x | -6.42 x | -13.1 x | -8.83 x | -3.95 x | -4.81 x | 2.97 x |
| EV / FCF | 93.2 x | 4.64 x | -6.12 x | -18 x | -7.45 x | -5 x | -5.32 x | 2.26 x |
| FCF Yield | 1.07% | 21.5% | -16.4% | -5.57% | -13.4% | -20% | -18.8% | 44.3% |
| Price to Book | 0.81 x | 0.94 x | - | - | 3.79 x | 10.5 x | -4.28 x | 4.03 x |
| Nbr of stocks (in thousands) | 14,767 | 14,926 | 17,920 | 18,259 | 18,488 | 21,569 | 21,569 | - |
| Reference price 2 | 3.400 | 3.700 | 7.200 | 10.28 | 6.675 | 5.560 | 5.560 | 5.560 |
| Announcement Date | 3/28/19 | 3/26/20 | 3/26/21 | 3/30/22 | 4/27/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.46 | 25.95 | 10.43 | 26.31 | 18.3 | 2.227 | 37.83 | 73.93 |
| EBITDA 1 | 4.963 | -1.149 | -18.56 | -14.29 | -15.65 | -20.41 | -34.6 | 40 |
| EBIT 1 | 4.847 | -1.472 | -18.99 | -16.62 | -18.39 | -22.98 | 6.434 | 45.96 |
| Operating Margin | 19.82% | -5.67% | -182.03% | -63.2% | -100.49% | -1,031.88% | 17.01% | 62.16% |
| Earnings before Tax (EBT) 1 | 4.707 | -1.464 | -19.25 | -17.21 | -18.02 | -23.22 | 25.3 | 33.7 |
| Net income 1 | 5.49 | -4.652 | -16.56 | -16.85 | -17.76 | -23 | -5.926 | 40.15 |
| Net margin | 22.45% | -17.93% | -158.69% | -64.05% | -97.04% | -1,032.91% | -15.66% | 54.3% |
| EPS 2 | 0.3500 | -0.3100 | -1.060 | -0.9300 | -0.9600 | -1.180 | -0.4300 | 2.000 |
| Free Cash Flow 1 | 0.484 | 8.799 | -19.49 | -10.39 | -18.53 | -30.7 | -31.3 | 52.6 |
| FCF margin | 1.98% | 33.9% | -186.8% | -39.5% | -101.22% | -1,023.33% | -82.73% | 71.15% |
| FCF Conversion (EBITDA) | 9.75% | - | - | - | - | - | - | 131.5% |
| FCF Conversion (Net income) | 8.82% | - | - | - | - | - | - | 131.02% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/26/20 | 3/26/21 | 3/30/22 | 4/27/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2023 S1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 15.98 | 5.849 | 4.583 | 8.975 | 17.33 | 1.358 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | -11.9 | -11.58 | -5.045 | - |
| Operating Margin | - | - | -259.74% | -129.03% | -29.11% | - |
| Earnings before Tax (EBT) | - | - | -12.04 | -11.76 | -5.452 | - |
| Net income 1 | - | - | -13.44 | -11.49 | -5.362 | -11.86 |
| Net margin | - | - | -293.28% | -128% | -30.94% | -873.34% |
| EPS 2 | 0.0300 | -0.2100 | -0.8500 | -0.6400 | -0.2900 | -0.6400 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/5/19 | 9/17/20 | 3/26/21 | 9/21/21 | 3/30/22 | 9/27/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 14.7 | 33.7 | 46.6 | - |
| Net Cash position 1 | 5.11 | 14.4 | 9.85 | 1.17 | - | - | - | 1.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.9397 x | -1.13 x | -1.347 x | - |
| Free Cash Flow 1 | 0.48 | 8.8 | -19.5 | -10.4 | -18.5 | -30.7 | -31.3 | 52.6 |
| ROE (net income / shareholders' equity) | 9.37% | -7.73% | -27.6% | - | -44.1% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.220 | 3.930 | - | - | 1.760 | 0.5300 | -1.300 | 1.380 |
| Cash Flow per Share 2 | 0.0700 | 0.6100 | -1.240 | -0.5500 | - | -0.1200 | 1.760 | 3.280 |
| Capex 1 | 0.59 | 0.34 | 0.21 | 0.47 | 0.27 | 0.28 | 0.32 | 0.35 |
| Capex / Sales | 2.42% | 1.29% | 2.01% | 1.79% | 1.5% | 9.44% | 0.84% | 0.47% |
| Announcement Date | 3/28/19 | 3/26/20 | 3/26/21 | 3/30/22 | 4/27/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.56
EUR
Average target price
7.15
EUR
Spread / Average Target
+28.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.91% | 128M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OSE Stock
- Financials OSE Immunotherapeutics
